Suppr超能文献

急性肾小管间质性肾炎诊断的生物标志物

Biomarkers for Diagnosis of Acute Tubulointerstitial Nephritis.

作者信息

Sadarangani Sagar, Mistry Kavita, Sise Meghan E, Moledina Dennis G

机构信息

Department of Internal Medicine, Section of Nephrology, Yale School of Medicine, New Haven, CT; Department of Internal Medicine, Clinical and Translational Research Accelerator, New Haven, CT.

Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

出版信息

Adv Kidney Dis Health. 2025 Jul;32(4):367-372. doi: 10.1053/j.akdh.2025.07.004.

Abstract

Acute tubulointerstitial nephritis (ATIN) is a common cause of acute kidney injury among patients who require a kidney biopsy. ATIN is an inflammatory reaction affecting the renal tubulointerstitium that occurs in response to medications, autoimmune diseases, or infections. ATIN is treated by removing the inciting agent and/or initiating immunosuppressive therapy. Kidney biopsy is often required to establish this diagnosis due to lack of pathognomonic clinical features and nonspecific clinical tests but carries a significant bleeding risk and may delay initiation of therapy. Thus, there is an important, unmet need for novel biomarkers that may facilitate the noninvasive diagnosis of ATIN. Since ATIN is characterized by renal tubulointerstitial inflammation, many immune-related soluble factors have been investigated as biomarkers for its diagnosis, including C-X-C motif ligand 9, tumor necrosis factor alpha, interleukin (IL)-9, regulated on activation, normal T cell expressed and secreted, monocyte chemoattractant protein-1, soluble IL-2 receptor alpha, IL-5, Fas receptor, and others. Imaging studies that reflect kidney inflammation have also been investigated. This review highlights the limitations of currently available tests for ATIN, the biomarkers currently under investigation, and the challenges associated with development and validation for their use in clinical practice.

摘要

急性肾小管间质性肾炎(ATIN)是需要进行肾活检的患者急性肾损伤的常见原因。ATIN是一种影响肾小管间质的炎症反应,可由药物、自身免疫性疾病或感染引发。ATIN的治疗方法是去除诱因和/或启动免疫抑制治疗。由于缺乏特征性临床特征和非特异性临床检查,通常需要进行肾活检来确诊,但肾活检有显著的出血风险,可能会延迟治疗的开始。因此,对于可能有助于ATIN无创诊断的新型生物标志物存在重要的未满足需求。由于ATIN的特征是肾小管间质炎症,许多免疫相关的可溶性因子已被研究作为其诊断的生物标志物,包括C-X-C基序配体9、肿瘤坏死因子α、白细胞介素(IL)-9、活化正常T细胞表达和分泌因子、单核细胞趋化蛋白-1、可溶性IL-2受体α、IL-5、Fas受体等。反映肾脏炎症的影像学研究也已被探讨。本综述强调了目前ATIN现有检测方法的局限性、正在研究的生物标志物以及在临床实践中开发和验证其应用所面临的挑战。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验